trending Market Intelligence /marketintelligence/en/news-insights/trending/qUbV88vVlHHjHjDSCVPfJQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bausch Health signs $5M deal for Clearside Biomedical's rejected eye drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Bausch Health signs $5M deal for Clearside Biomedical's rejected eye drug

Bausch Health Companies Inc. will acquire licensing rights to Clearside Biomedical Inc.'s investigational eye inflammation drug Xipere, which was rejected by the U.S. Food and Drug Administration on Oct. 21.

Xipere is being developed as a treatment for macular edema associated with uveitis, a condition in which fluid builds up in a part of the eye and leads to loss of vision.

Laval, Quebec-based Bausch will pay $5 million up front and up to $15 million in payments before the launch of Xipere, plus certain milestone payments thereafter.

Bausch said Clearside expects to resubmit the application for Xipere to the FDA in the first quarter of 2020.

Until the application is approved, Clearside will be responsible for all development expenses related to Xipere. Bausch will handle development expenses once the therapy is approved.

The FDA asked Clearside to provide additional stability data on the new manufacturing process for Xipere, an injectable form of a synthetic corticosteroid called triamcinolone acetonide.